Colorectal Cancer, NSCLC, Breast and Ovarian Cancer Represent the Most Common Indications Targeted By Drugs in Development

The biotechnology index for the last 5 days.


The Cancer Market Outlook To 2011

DUBLIN, Ireland-Nov 8, 2006 - Research and Markets has announced the addition of The Cancer Market Outlook to 2011 to their offering.

Innovation is the key driving force in the cancer market, creating strong opportunities for biotech and pharma companies to launch new products and benefit from high volume sales and a strong competitive position.

'The Cancer Market Outlook to 2011' provides detailed analysis on 9 indications in the cancer market, identifying growth brands, key drug classes and leading companies.

The 6-year epidemiology and product sales forecasts detailed in this report will enable you to evaluate the changes in the competitive positions of leading companies in the cancer market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth.

Use this report to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2006-2011.

Key findings of the report...

-- New launches such as Erbitux, Avastin and Tarceva are set to continue to drive the rapid growth of the innovative market due to their utility across multiple indications, and superior efficacy profiles.

-- Colorectal cancer, NSCLC, breast and ovarian cancer represent the most common indications targeted by drugs in development, with an increasing focus also around indications such as renal cell carcinoma and NHL, which while offering a small patient base pose significant incentives if molecules are granted orphan drug status.

-- The cytostatic hormonals market, which has benefited from strong growth over the previous five years, no longer appears to be the growth driver it once was, as generic competition and a lack of innovation reduces prospects for growth.

-- Product and development failure, low investment in emerging technologies and various R&D pipeline constructs are forecast to catalyze a shift in the top players over the forecast period. While Roche is forecast to extend its leading position within the cancer market through strong sales of MabThera, Avastin, Herceptin, Pegasys and Tarceva, increasing genericization is expected to cannibalize AstraZeneca's cancer franchise.